COVID-19 vaccination and cardiac dysfunction

Table 2 Characteristic of acute myocarditis patients after coronavirus disease 2019 mRNA vaccination

Ref.	Type of vaccine	No. of myocarditiscases	Male/Female (%)	Median age in yr (IQR)	Myocarditis after 1st dose (%)	Myocarditis after 2nd dose (%)	Clinical severity F/I/M
Witberg et al[11], Israel	Pfizer-BioNTech	54	51/3 (94/6)	27 (21–35)	17 (31.48)	37 (68.52)	1/12/41
Mevorach et al[12], Israel	Pfizer-BioNTech	136	118/18 (87/13)	- (16-> 30)	19 (13.97)	117 (86.03)	1/6/129
Montgomery et al[13], United States	Pfizer-BioNTech/Moderna	23	23/0 (100/0)	25 (20-51)	3 (13.04)	20 (86.96)	0/7/16
Perez et al[14], United States	Pfizer-BioNTech/Moderna	7	6/1 (86/14)	44 (22-71)	1 (14.29)	6 (85.71)	0/6/1
Das et al[15], United States	Pfizer-BioNTech	25	22/3 (88/12)	15 (12-17)	3 (12.00)	22 (88.00)	0/22/3
Simone et al[18], United States	Pfizer-BioNTech/Moderna	15	15/0 (100/0)	25 (20-32)	2 (13.33)	13 (86.67)	0/15/0
Nygaard et al[19], Denmark	Pfizer-BioNTech	15	13/2 (87/12)	17 (13-17)	8 (53.33)	7 (46.67)	0/1/14
Diaz et al[21], United States	Pfizer-BioNTech/Moderna	20	15/5 (75/25)	36 (26-48)	4 (20.00)	16 (80.00)	2/17/1

F/I/M: Fulminant/intermediate/mild; IQR: Interquartile range.